Cargando…
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
BACKGROUND: Retention rate, efficacy, and safety of abatacept (ABA) was compared between patients with rheumatoid arthritis receiving ABA as monotherapy to those in combination ABA + conventional synthetic DMARD (csDMARD). METHODS: The patients were obtained from the ORA registry. The retention rate...
Autores principales: | Truchetet, Marie-Elise, Poursac, Nicolas, Barnetche, Thomas, Shipley, Emilie, Gottenberg, Jacques-Eric, Bannwarth, Bernard, Richez, Christophe, Schaeverbeke, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815200/ https://www.ncbi.nlm.nih.gov/pubmed/27029339 http://dx.doi.org/10.1186/s13075-016-0956-7 |
Ejemplares similares
-
Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017) -
Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008) -
Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006) -
Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011) -
Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)